The aging of the world’s population along with improved survival rates will cause the number of people living with amyotrophic lateral sclerosis (ALS) to rise sharply over the next 15 years, according to a new study published in Annals of Clinical and Transitional Neurology. The study — Amyotrophic Lateral Sclerosis Prevalence Projection in 2040: A…
Not So Rare: Study Says Number of People Living with ALS Will Jump in Next 15 Years
Study Calculates First-Year Costs for Newly Diagnosed ALS Medicare Beneficiaries
New ALS patients had higher costs for acute care, prescription medications and durable medical equipment.
A new study has revealed the financial costs for patients with amyotrophic lateral sclerosis (ALS) in the first year after diagnosis. The research led by the ALS Association and published in the October edition of The American Journal of Managed Care said the average Medicare beneficiary diagnosed with ALS racked up first-year medical expenses of…
Researchers: ALS Patients with Diabetes Quicker to Lose Ability to Walk
The study’s authors recommended “early implementation” of walking aids for ALS patients with a history of diabetes.
Patients who had diabetes when diagnosed with amyotrophic lateral sclerosis (ALS) were on average quicker to lose their ability to walk compared to ALS patients without diabetes. Japanese researchers published their study — Factors Influencing the Loss of Ambulation in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Cohort Study — in Health Science Reports in…
Briefly: munevo, Permobil Sign European Partnership; Neuralink Announces New Investor
Featuring munevo, Permobil, Neuralink, and CoreNest Capital.
munevo Announces Permobil Partnership in Europe munevo has announced a new partnership with Permobil for its DRIVE system, a smartglasses alternative driving control for power wheelchairs. “In this partnership, we combine our technologies to offer people a new dimension of freedom and self-determination – for greater mobility, participation, and quality of life,” munevo said in…
Briefly: Researchers Find a Cause for Familial ALS; ADA’s 35th Anniversary Upcoming
Featuring Okayama University and the ADA National Network.
Researchers: Gene that Maintains Protein Quality Linked to Familial ALS Japanese researchers based at Okayama University have discovered a cause of familial amyotrophic lateral sclerosis (ALS), the Asahi Shimbun newspaper has reported. In the July 1 story, Associate Professor Toru Yamashita and Professor Hiroyuki Ishiura from Okayama University’s medical school said that when a gene…
Researchers: Polyunsaturated Fatty Acids Could Lessen ALS Nerve Damage
Study results suggest lowered risk of motor neuron diseases among people with a high intake of omega-3 fatty acids.
Results of a new study led by researchers at the University College London’s (UCL) UK Dementia Research Institute and the UCL Institute of Healthy Aging showed that increasing the levels of polyunsaturated fatty acids in the brain cells of fruit flies with a certain gene mutation had a “dramatic” increase in their survival. The study…
Briefly: ISS 2025 App Now Available; New ALS Navigator Helps Patients, Families with Insurance Denials
Featuring the International Seating Symposium and the ALS Association.
ISS 2025 App Now Available If you’re heading to Pittsburgh next week, download the International Seating Symposium’s (ISS) app to keep track of your educational sessions, meetings, and conference events. The cvent events app is free to download and is available in the Apple App Store and Google Play Store. Scan the QR code to…
Briefly: Florida University Receives ALS Gift; Medtrade to Feature CRT Live Demos
Featuring Nova Southeastern University and Medtrade.
Philanthropist Pledges $20 Million to Florida University for ALS Work Nova Southeastern University (NSU) has received a $20 million bequest from a philanthropist whose late wife had amyotrophic lateral sclerosis (ALS). In a Jan. 9 news announcement, NSU, based in Fort Lauderdale, Florida, said the gift came from David Husman, founder and chairman of Heartland…
New Biopharmaceutical Company to Work on UNC13A Protein Cure to ALS
The startup has secured $101 million in funding to pursue a treatment that could impact 97% of ALS patients.
Trace Neuroscience, a biopharmaceutical launch based in South San Francisco, is targeting the UNC13A protein as a possible treatment path for amyotrophic lateral sclerosis (ALS) and other neurogenerative diseases. In a Nov. 12 press release, the company said UNC13A “is a genetically validated target with the potential to treat 97% of people living with ALS.”…
Briefly: CMS Adds Inclusion Body Myositis to Seating Consideration List; Nonprofit Debuts Caregiver Website
Featuring NCART, the Centers for Medicare & Medicaid Services, and I AM ALS.
CMS Adds Inclusion Body Myositis ICD-10 Code for Seating Considerations The National Coalition for Assistive & Rehab Technology (NCART) has reported that the Centers for Medicare & Medicaid Services (CMS) has added the ICD-10 code for inclusion body myositis (G72.41) to the Group 2 and Group 4 lists for consideration for a skin protection and/or…